🔎 Trials Near Me

홈 › 두경부 편평세포암 › 미네소타

미네소타의 두경부 편평세포암 임상 시험

두경부 편평세포암 관련 연구 25개가 미네소타 내 여러 지역에서 참여자를 모집하고 있습니다.

미네소타의 도시

공식 연구 텍스트(영어)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

  • Sanford Joe Lueken Cancer Center, Bemidji
피험자 모집 중2상
18세 ~ 79세 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04671667

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Minnesota Oncology - Burnsville, Burnsville
  • 외 20개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05136196

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Minnesota Oncology - Burnsville, Burnsville
  • Mercy Hospital, Coon Rapids
  • 외 8개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06589804

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Sanford Joe Lueken Cancer Center, Bemidji
  • Mayo Clinic Health Systems-Mankato, Mankato
  • 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06992427

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  • Site #0156, Maplewood
  • Mayo Clinic Cancer Center - Rochester (Site #0146), Rochester
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06788990

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Mayo Rochester, Rochester
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT07109726

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • M Health Fairview University of Minnesota Medical Center, Minneapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06330064

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 121, Saint Paul
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05914116

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  • Mayo Clinic in Rochester, Rochester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07768189

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #68, Rochester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05176483

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Minnesota Oncology and Hematology PA, Minneapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT05267626

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • 외 48개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT02734537

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Mayo Clinic (Rochester), Rochester
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

  • Mayo Clinic, Rochester
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT06657222

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

  • Mayo Clinic Rochester, Rochester
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06163534

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • University of Minnesota Masonic Cancer Center, Minneapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07216105

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Minneapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07182149

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

  • Mayo Clinic in Rochester, Rochester
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT04333537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  • Miller-Dwan Hospital, Duluth
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT06532279

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
  • Allina Health Cancer Institute - United Hospital, Saint Paul
  • 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT04389632

Oropharynx (OPX) Biomarker Trial

  • Mayo Clinic in Rochester, Rochester
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT06356272

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  • Mayo Clinic, Rochester
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 9. 9. 업데이트됨 · NCT06682793

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

  • Mayo Clinic Rochester, Rochester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2024. 9. 24. 업데이트됨 · NCT06259552

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.